❌

Normal view

Insulin resistance prediction from wearables and routine blood biomarkers

Nature, Published online: 16 March 2026; doi:10.1038/s41586-026-10179-2

A machine-learning model that integrates data from wearable devices (such as smartwatches) with blood biomarkers and demographic data can predict whether someone has insulin resistance, enabling timely lifestyle interventions to prevent progression to type 2 diabetes.
  • ✇Nature Medicine
  • The AI co-scientist is here David Adam
    Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04275-zArtificial intelligence models are evolving from chats to hypotheses. Now their ideas are being validated in organoids and animals — and even in early-stage clinical trials.
     

First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature Medicine, Published online: 16 March 2026; doi:10.1038/s41591-026-04306-9

In cohort 4 of the ILUSTRO trial, combination of anti-CLDN18.2 zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive, HER2-negative metastatic gastric or gastroesophageal junction adenocarcinoma led to encouraging clinical efficacy, supporting the testing of this combination in a phase 3 trial.
❌